Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4192-4200

  Weiner, Marc ^a   Peloquin, Charles ^b   Burman, William ^c   Luo, Chi Cheng ^d   Engle, Melissa ^a   Prihoda, Thomas J ^a   Mac Kenzie, William R ^d   Bliven Sizemore, Erin ^d   Johnson, John L ^e   Vernon, Andrew ^d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c DENVER PUBLIC HEALTH   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AFRICA; AFRICAN AMERICAN; AGED; AREA UNDER THE CURVE; ARTICLE; BIOGEOGRAPHIC REGION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; GENE; GENETIC ANALYSIS; GENOTYPE; GLYCOPROTEIN P GENE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NORTH AMERICA; ORGANIC ANION TRANSPORTER 1 GENE; ORGANIC ANION TRANSPORTER 3 GENE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

ADULT; AFRICA; ANTIBIOTICS, ANTITUBERCULAR; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NORTH AMERICA; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RIFAMPIN; SPAIN; TUBERCULOSIS; YOUNG ADULT;

EID: 77957336059     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00353-10     Document Type: Article

References (33)

1. Borin, M. T., J. T. Chambers, B. J. Carel, S. Gagnon, and W. W. Freimuth. 1997. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin. Pharmacol. Ther. 61:544-553.
2. Buniva, G., V. Pagani, and A. Carozzi. 1983. Bioavailability of rifampicin capsules. Int. J. Clin. Pharmacol. Ther. Toxicol. 21:404-409.
3. Burman, W. J., S. Goldberg, J. L. Johnson, G. Muzanye, M. Engle, A. W. Mosher, S. Choudhri, C. L. Daley, S. S. Munsiff, Z. Zhao, A. Vernon, and R. E. Chaisson. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:331-338.
4. Burman, B., K. Gallicano, and C. Peloquin. 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40:327-341.
5. Chang, K. C., C. C. Leung, W. W. Yew, S. L. Chan, and C. M. Tam. 2006. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:1153-1158.
6. Chatterjee, P. 2001. India's trade in fake drugs - bringing the counterfeiters to book. Lancet 357:1776. (Pubitemid 32524225)
7. Choudhri, S. H., M. Hawken, S. Gathua, G. O. Minyiri, W. Watkins, J. Sahai, D. S. Sitar, F. Y. Aoki, and R. Long. 1997. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS and diarrhea. Clin. Infect. Dis. 25:104-111.
8. Conte, E. Jr., J. A. Golden, J. E. Kipps. E. T. Lin, and E. Zurlinden. 2004. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Clin. Pharmacokinet. 43:395-404.
9. Dorman, S. E., J. L. Johnson, S. Goldberg, G. Muzanye, N. Padayatchi, L. Bozeman, C. M. Heilig, J. Bernardo, S. Choudhri, J. H. Grosset, E. Guy, P. Guyadeen, M. C. Leus, G. Maltas, D. Menzies, E. L. Nuermberger, M. Villarino, A. Vernon, R. E. Chaisson, and the Tuberculosis Trials Consortium. 2009 Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 180:273-280.
10. Ellard, G. A., and P. B. Fourie. 1999. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int. J. Tuber. Lung Dis. 3(Suppl. 3):S301-S308.
11. Englund, G., F. Rorsman, A. Ronnblom, U. Karlbom, U. L. Lazorova, J. Gråsjö, A. Kindmark, and P. Artursson. 2006. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci. 29:269-277.
12. Fox, W. 1990. Drug combinations and the bioavailability of rifampicin. Tubercle 71:241-245.
13. Glaeser, H., D. G. Bailey, G. K. Dresser, J. C. Gregor, U. I. Schwarz, J. S. McGrath, E. Jolicoeur, W. Lee, B. F. Leake, R. G. Tirona, and R. B. Kim. 2007. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharm. Ther. 81:362-370.
14. Grosset, J. H., I. M. Rosenthal, M. Zhang, and E. L. Nuermberger. 2008. Dose-ranging comparison of rifampin and rifapentine in combination with isoniazid and pyrazinamide in the mouse model of tuberculosis, abstr. A-1825. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
15. He, Y. J., W. Zhang, Y. Chen, D. Guo, J. H. Tu, L. Y. Xu, Z. R. Tan, B. L. Chen, Z. Li, G. Zhou, B. N. Yu, J. Kirchheiner, and H. H. Zhou. 2009. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin. Chim. Acta 405:49-52.
16. Jamis-Dow, C. A., A. G. Katki, J. M. Collins, and R. W. Klecker. 1997. Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica 27:1015-1024.
17. Jayaram, R., S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharat, R. K. Shandil, E. Kantharaj, and V. Balasubramanian. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124.
18. Ji, B., C. Truffot-Pernot, C. Lacroix, M. C. Raviglione, R. J. O'Brien, P. Olliaro, G. Roscigno, and J. H. Grosset. 1993. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am. Rev. Respir. Dis. 148:1541-1546.
19. Lau, Y. Y., Y. Huang, L. Frassetto, and L. Z. Benet. 2007. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharm. Ther. 81:194-204.
20. Li, J., S. S. Munsiff, C. R. Driver, and J. Sackoff. 2005. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin-or rifabutin-based regimens in New York City, 1997-2000. Clin. Infect. Dis. 41:83-91.
21. McIlleron, H., P. Wash, A. Burger, J. Norman, P. I. Folb, and P. Smith. 2006. Determinants of rifampin, isoniazid, pyrazinamide and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50:1170-1177.
22. Peloquin, C. A., R. Namdar, M. D. Singleton, and D. E. Nix. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18.
23. Pinheiro, V. G. F., L. M. A. Ramos, E. C. Barroso, L. M. A. Ramos, H. S. A. Monteiro, O. Y. Bushen, M. C. Façanha, C. A. Peloquin, R. L. Guerrant, and A. A. M. Lima. 2006. Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis. Braz. J. Infect. Dis. 10:374-379.
24. Rosenthal, I. M., K. Williams, S. Tyagi, C. A. Peloquin, A. A. Vernon, W. R. Bishai, J. H. Grosset, and E. L. Nuermberger. 2006. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am. J. Respir. Crit. Care Med. 174:94-101.
25. Rosner, B. 2006. Fundamentals of biostatistics, 6th ed. Duxbury Press, Belmont, CA.
26. Song, P., S. Li, B. Meibohm, A. O. Gaber, M. R. Honaker, M. Kotb, and C. R. Yates. 2002. Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. AAPS PharmSci. 4:E29.
27. Tappero, J. W., W. Z. Bradford, T. B. Agerton, P. Hopewell, A. L. Reingold, S. Lockman, A. Oyewo, E. A. Talbot, T. A. Kenyon, T. L. Moeti, H. J. Moffat, and C. A. Peloquin. 2005. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin. Infect. Dis. 41:461-469.
28. Tirona, R. G., B. F. Leake, A. W. Wolkoff, and R. B. Kim. 2003. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharm. Exp. Ther. 304:223-228.
29. van Crevel, R., B. Alisjahbana, W. C. M. de Lange, F. Borst, H. Danusantoso, J. W. M. Meer, D. van der, Burger, and R. H. H. Nelwan. 2002. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int. J. Tuber. Lung Dis. 6:497-502.
30. Weiner, M., C. Peloquin, W. Burman, C. C. Luo, M. Engle, T. Prihoda, W. Mac Kenzie, E. Bliven, J. Johnson, and A. Vernon. 2009. The effects of tuberculosis infection, race and human gene SLCO1B1 polymorphisms on rifampin concentrations. Abstr. Virology-Education Second International Workshop Clin. Pharmacol. Tuberc. Drugs, San Francisco, CA, 11 September 2009.
31. Weiner, M., C. Peloquin, J. Johnson, W. Burman, T. Prihoda, N. Padayatchi, S. Goldberg, M. Engle, G. Muzanye, and the Tuberculosis Trials Consortium. 2008. Pharmacokinetics of rifampin and moxifloxacin in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 177(Suppl.):A791.
32. Weiner, M., W. Burman, C. C. Luo, C. A. Peloquin, M. Engle, S. Goldberg, V. Agarwal, and A. Vernon. 2007. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob. Agents Chemother. 51:2861-2866.
33. Weiner, M., D. Benator, W. Burman, C. A. Peloquin, A. Khan, A. Vernon, B. Jones, C. Silva-Trigo, Z. Zhao, T. Hodge and Tuberculosis Trials Consortium. 2005. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40:1481-1491.